According to a recent LinkedIn post from HistoSonics, the company is using the upcoming Society of Interventional Radiology meeting in Toronto to spotlight clinical experience with its histotripsy technology. The post highlights a breakfast symposium titled “Histotripsy in Practice: Real-World Experience, Evidence, and Future Frontiers,” featuring interventional radiologists from several major U.S. health systems.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that HistoSonics representatives plan to be available at the conference exhibition to discuss the Edison Histotripsy System and a supporting Samsung R20 ultrasound platform. A disclaimer in the post indicates that use of the Edison System outside liver applications is currently limited to clinical investigations, implying the technology’s broader indications remain in development.
For investors, this activity suggests HistoSonics is prioritizing physician engagement and real-world education as it moves histotripsy from early innovation toward practical adoption. Showcasing multiple academic and hospital users may help build clinical credibility, which can be a key driver for future procedure volume, reimbursement consideration, and potential commercial partnerships.
The focus on a dedicated system and defined imaging companion underscores a strategy centered on an integrated therapeutic platform. If physician interest at forums such as the SIR meeting translates into increased trial participation and adoption within approved indications, HistoSonics could strengthen its position in the interventional oncology and minimally invasive therapy markets over the medium term.